Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IXT-011
- Development stage
- Preclinical
- Lead developer
- invoX Pharma
- Modality
- Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
IXT-011 is an investigational drug candidate being developed by invoX Pharma for the treatment of Idiopathic Pulmonary Fibrosis (IPF). It is formulated for delivery via the proprietary Softhaler® platform, a high-efficiency dry powder inhalation technology designed to optimize drug deposition in the deep lungs while maintaining ease of use for patients. As of current public disclosures, the specific molecular target and the nature of the active pharmaceutical ingredient (whether a small molecule, peptide, or other biologic) have not been revealed. The program is part of invoX Pharma's broader respiratory pipeline, which focuses on leveraging localized inhalation delivery to improve the therapeutic index of treatments for chronic pulmonary diseases.
- Other names
- Inhaled nintedanib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on IXT-011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IXT-011.